CMBA
HBIO icon

C.M. Bidwell & Associates’s Harvard Bioscience HBIO Stock Holding History

C.M. Bidwell & Associates’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-120
Closed -$6K – 413
2018
Q2 		$6K Sell
120
-2,533
-95% -$130K 0.01% 328
2018
Q1 		$133K Buy
+2,653
New +$119K 0.12% 171

Other funds holding HBIO

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

C.M. Bidwell & Associates's HBIO Position: Q3 2018 in Review

C.M. Bidwell & Associates sold out of Harvard Bioscience (HBIO) in Q3 2018, closing a stake of 120 shares — an estimated $6K sold.

C.M. Bidwell & Associates first reported a position in HBIO in Q1 2018 and held it in 2 quarters. The position peaked at $133K in Q1 2018. 94 funds tracked by Wall St. Rank hold HBIO as of Q3 2018.

  • C.M. Bidwell & Associates reported no remaining Harvard Bioscience position as of Q3 2018 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 120 Harvard Bioscience shares in Q3 2018, an estimated $6K.
  • C.M. Bidwell & Associates first reported a position in Harvard Bioscience in Q1 2018 and held it in 2 quarters.
  • C.M. Bidwell & Associates's Harvard Bioscience position peaked at $133K in Q1 2018.
  • 94 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2018.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2018, filed 13 Nov 2018.